|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
SRC-1 expression in aggressive pheochromocytomas, may also be a potential diagnostic pitfall in view of the fact that these tumors may be misinterpreted as ACC in the primary or metastatic setting.
|
31633491 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Western blot assays showed complete activation of downstream signal pathways up to p-SRC proto-oncogene tyrosine-protein kinase, and p-focal adhesion kinase recruitment in MET and ALK-coamplified tumors only, whereas isolated MET amplification, MET and ALK borderline amplification (5%-10% of tumor cells with ≥15 copies of the relevant gene), or negative tumors showing eusomy or chromosome polysomy were confined to p-mitogen-activated protein kinase, p-protein kinase B, and/or p-MET activation.
|
26804638 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In particular, c-SRC may be an attractive therapeutic target for tumors harboring EGFRvIII as we identified this protein specifically mediating angiogenic tumor growth downstream of EGFRvIII.
|
27286795 |
2016 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Archival tumor tissue was evaluated for expression of the proto-oncogene tyrosine-protein kinase Src (SRC), phosphorylated SRC (pSRC), and succinate dehydrogenase complex iron sulfur subunit B (SDHB) proteins and for mutation in the V-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) and platelet-derived growth factor receptor α (PDGFRA) genes.
|
29710216 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
|
26676753 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
While pp60c-src was found in most tumors studied, the neuronal form was restricted to neuroblastomas (23 of 27) and retinoblastomas (3 of 3) and could not be detected in the other childhood tumors.
|
1698545 |
1990 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
We show that miR-135b overexpression is triggered in mice and humans by APC loss, PTEN/PI3K pathway deregulation, and SRC overexpression and promotes tumor transformation and progression.
|
24735923 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Moreover, CR-CaP [Src-shRNA] tumors that recurred had similar Src protein and activation levels as those of parental cells, strengthening the notion that Src activity is required for progression to CR-CaP.
|
24403252 |
2013 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The exact localization of SRC is important for understanding the del(20q) chromosomal abnormality in myeloid neoplasias.
|
2506951 |
1989 |
|
Neoplasms
|
0.200 |
PosttranslationalModification
|
group |
BEFREE |
These findings suggest that loss of PTPN23 may increase the activity of SRC and the phosphorylation status of the E-cadherin/β-catenin signaling complex to promote tumor growth and invasive behavior in breast cancer.
|
21724833 |
2011 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
These agents synergized to reduce tumor vascularity and endothelial cell growth and migration by blocking activation of FAK and SRC.
|
31841591 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Available data on agents potentially targeting bone metastatic CRPC or the bone microenvironment in patients with CRPC are discussed, including inhibitors of tumor growth/survival and bone turnover (SRC family kinase inhibitors, endothelin-1 inhibitors, MET inhibitors, and thalidomide and its derivatives), inhibitors of bone turnover (bisphosphonates and receptor activator of nuclear factor-kB ligand inhibitors), antiangiogenic agents (vascular endothelial growth factor receptor and platelet-derived growth factor blockers), prostate cancer vaccines, and bone-directed radiopharmaceuticals.
|
22267211 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Taken together, our findings suggest that SRC-1 switches steroid-responsive tumors to a steroid-resistant state in which the SRC-1 target gene ADAM22 has a critical role, suggesting this molecule as a prognostic and therapeutic drug target that could help improve the treatment of endocrine-resistant breast cancer.
|
22072566 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Clinical trials with SRC family kinases (SFKs) inhibitors used alone or in a combination with anti-CD20 monoclonal antibodies (mAbs) are currently underway in the treatment of B-cell tumors.
|
25517315 |
2014 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The ups and downs of SRC regulation: tumor suppression by Cbp.
|
18538730 |
2008 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Decreased AR activity was also related to the expression of SRC kinase, and sensitivity to dasatinib.The work by Mendiratta et al. may be useful to determine the AR status of tumors in order to inform therapy and individualize treatment.
|
19838047 |
2009 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
SLIRP is expressed in normal and tumor tissues, contains an RNA recognition motif (RRM), represses NR transactivation in a SRA- and RRM-dependent manner, augments the effect of Tamoxifen, and modulates association of SRC-1 with SRA.
|
16762838 |
2006 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.
|
24994118 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The sentence should read 'In mouse mammary tumour models, increased collagen levels and increased β1 integrin and SRC activity have been demonstrated to accompany, and promote, combined resistance to anti-human epidermal growth factor receptor 2 (HER2; also known as ERBB2) (trastuzumab and pertuzumab) and anti-PI3K (buparlisib) therapies164.'
|
30705430 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Addition of the c-SRC transgene to the p21-/- background increased tumor formation almost 3-fold, while it increased metastasis 6-fold.
|
18351644 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The two human papillomavirus (HPV) 16 flanking sequences derived from the tumor were localized to chromosome regions 20pter----20q13 and 3p25----3qter, regions that also contain the protooncogenes c-src-1 and c-raf-1, respectively.
|
3029760 |
1987 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
To evaluate treatment response, survival, and the associations between KRAS mutation status and tumour expression levels of BRCA1, TYMS and SRC retrospectively in a cohort of patients with non-small cell lung cancer (NSCLC), treated exclusively with conjunctive platinum-based doublet chemotherapy.
|
26740498 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Deregulated SRC/FAK signaling leads to enhanced migration and invasion in many types of tumors.
|
29190494 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Hence, enforced expression of an activated SRC combined with p53 inactivation induces murine tumors that resemble group 4 medulloblastoma.
|
30205043 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Overexpression and/or oncogenic mutation in the Src gene have been documented in human tumors.
|
23851499 |
2014 |